Can Fite Biopharma Aktie [WKN DE: A1W6SX / ISIN: US13471N1028]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Can Fite Biopharma Ltd (spons. ADRs)

06.01.20		Can-Fite CEO Issues Letter to Shareholders (Businesswire)
03.01.20		New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss (Businesswire)
26.12.19		Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing (Businesswire)
09.12.19		Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial (Businesswire)
05.12.19		Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH (Businesswire)
29.11.19		Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update (Businesswire)
21.11.19		Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019 (Businesswire)
19.11.19		Can-Fite Granted Patents for its Sexual Dysfunction Drug (Businesswire)
11.11.19		Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market (Businesswire)
04.11.19		Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients (Businesswire)
31.10.19		U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer (Businesswire)
17.10.19		Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis (Businesswire)
16.10.19		Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report (Businesswire)
15.10.19		Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™ (Businesswire)
10.10.19		Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine (Businesswire)
23.09.19		Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference (Businesswire)
10.09.19		Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays (Businesswire)
29.08.19		Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update (Businesswire)
06.08.19		Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel (Businesswire)
04.06.19		Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019 (Businesswire)
03.06.19		Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session (Businesswire)
29.05.19		Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update (Businesswire)
23.05.19		The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin (Businesswire)
20.05.19		Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA) (Businesswire)
06.05.19		Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson (Businesswire)
01.05.19		Can-Fite Announces ADS Ratio Change (Businesswire)
15.04.19		Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea (Businesswire)
10.04.19		Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting (Businesswire)
02.04.19		Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering (Businesswire)
29.03.19		Can-Fite Files Annual Report for the Year Ended December 31, 2018 (Businesswire)
28.03.19		Can-Fite Reports 2018 Financial Results & Provides Clinical Update (Businesswire)
26.03.19		Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson (Businesswire)
27.02.19		Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo (Businesswire)
25.02.19		Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication (Businesswire)
04.02.19		Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug (Businesswire)
30.01.19		Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal (Businesswire)
24.01.19		Can-Fite BioPharma CEO Letter to Shareholders (Businesswire)
18.01.19		Can-Fite BioPharma Announces Registered Direct Offering (Businesswire)
08.01.19		Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent (Businesswire)
03.01.19		Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference (Businesswire)
20.11.18		Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert (Businesswire)
31.10.18		Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19 (Businesswire)
25.10.18		Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference (Businesswire)
18.10.18		Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018 (Businesswire)
12.09.18		Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD) (Businesswire)
04.09.18		Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year (Businesswire)
31.08.18		Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update (Businesswire)
29.08.18		Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (Businesswire)
21.08.18		Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis (Businesswire)
07.08.18		Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin als Chance: MicroStrategy-Chef fordert Microsoft zu mutigem Schritt auf

CompuGroup-Aktie mit zweistelligem Plus: CVC bestätigt Akquisition

Bayer-Aktie erholt sich weiter: Glyphosat-Fehlprozess in USA

Neue Kooperationsvereinbarung: Palantir-Aktie erreicht neues Rekordhoch - und sackt dann ab

Generative KI: Warum der NVIDIA-CEO auf Accenture setzt

voestalpine-Aktie gewinnt: Wiener Privatbank senkt Kursziel

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	11.12.2024 23:22
Kaufwert:	EUR
	Hinzufügen Speichern